1Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy[ J]. J Clin Oncol, 1993,11(1) : 116-124.
2Ossenkoppele EJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to Ara-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients[J]. Blood, 2004, 103 (8) :2 908-2 913.
3Hubeek I,Litvinova E, Peters GJ,et al. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia[ J]. Int J Oncol, 2004,25 ( 6 ) : 1 823-1 829.
4Gazitt Y. Homing and mobilization of hematopoietic stem ceils and hematopoieric cancer cells are mirror image processes, utilizing similar signaling path- ways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specillc antibodies[ J ]. Leukemia, 2004,18 ( 1 ) : 1-10.
5Higashi Y, Turzanski J, Pallis M, et al. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside(Ara-C) and granulocyte colony- stimulating factor(FLAG) compared with daunorubicin and Ara-C in P-glyco- protein-positive and P-glycoprotein-negative acute myeloblastic leukaemia[J]. Br J Haematol,2000,111(2) :565-569.
7Pastore D,Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience[J]. Ann Hematol, 2003,82(4) : 231-235.
3[1]Gandhi V,Estey E,Keating MJ,et al.Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.J Clin Oncol,1993,11:116
4[2]Jackson GH.Use of fludarabine in the treatment of acute myeloid leukemia.Hematol J,2004,5 Suppl 1:S62-7
